European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 23 · Tue 17 Nov 

Companies

GH Research

GH Research Ireland Limited

HQ
Ireland
Registry
SEC EDGAR (parent GH Research PLC) · CIK 1855129
Status
active
Listing
Listed
Current stage
Phase 2b complete in TRD

sec.govregistryverified 2026-11-02

Notes on the record

Ticker not verified this session; left blank rather than guessed. Holds the only EudraCT numbers in our BPL-003/mebufotenin/VLS-01 sweep, both on its own trials, which is why an EU identifier in that result set does not belong to AtaiBeckley. Renamed 2026-09-01 from company_id C006-gh-research to C006-gh. The id is the key the site derives this company's archive tag from, and GH-RESEARCH read long beside LILLY and COMPASS. Renamed in place rather than superseded with a second row, because two rows would derive two tags for one company; nothing else in data/ or issues/ referenced the old id, checked before the change, and the git history carries it. Supersedes the earlier row. Parent and SEC registrant is GH Research PLC (Dublin), Form 20-F filer. 6-K filed 2026-09-11: one-on-one investor meetings at the Morgan Stanley 24th Annual Global Healthcare Conference, 14 to 16 September 2026, New York. Form 4 filed 2026-09-09: director Florian Schonharting granted 2,303 share options at $0.025 on 2026-09-08, fully vested, exercisable from 2028-09-08. RE-VERIFIED 2026-11-02, no field changed: EDGAR CIK 1855129 (GH Research PLC), one filing since the earlier row, 6-K 0001140361-26-039191 of 2026-10-09 (ECNP posters, 11 October 2026). Supersedes the row verified 2026-09-15 (kept), per DATA LAYER rule 4.

Assets

Registered trials

  • NCT05800860ClinicalTrials.gov

    PHASE2 · Treatment-resistant Depression · COMPLETED · Czechia, Germany, Ireland, Netherlands, Poland, Spain

    clinicaltrials.govctgov registryverified 2026-08-31

  • NCT05804708ClinicalTrials.gov

    PHASE2 · Postpartum Depression;Postnatal Depression · TERMINATED · Netherlands, United Kingdom

    clinicaltrials.govctgov registryverified 2026-08-31

  • NCT05839509ClinicalTrials.gov

    PHASE2 · Bipolar II Disorder · TERMINATED · Germany, Netherlands, United Kingdom

    clinicaltrials.govctgov registryverified 2026-08-31

  • 2023-510047-37-00CTIS

    Therapeutic exploratory (Phase II) · Treatment-resistant depression (TRD) · Ended · Czechia, Germany, Ireland, Poland, Spain

    euclinicaltrials.euctis registryverified 2026-08-31

  • NCT06511947ClinicalTrials.gov

    PHASE1 · Healthy Volunteers · TERMINATED · United Kingdom

    clinicaltrials.govctgov registryverified 2026-10-19

  • NCT07540494ClinicalTrials.gov

    PHASE1 · Healthy Adult · COMPLETED · United States

    clinicaltrials.govctgov registryverified 2026-10-19

Deals

This company is not a party to any row in data/deals.csv.

In the briefing

3 issues tagged GH.

Record history